Interim Healthcare Of Western Pa | |
127 North Brady Street Ste B, Dubois, Pennsylvania 15801 | |
(814) 375-9615 | |
Not Available |
Name | Interim Healthcare Of Western Pa |
---|---|
Location | 127 North Brady Street Ste B, Dubois, Pennsylvania |
Certified By | Medicare |
Services Offered | Nursing Care Physical Therapy Occupational Therapy Speech Pathology Medical Social Services Home Health Aide |
Medicare ID | 397647 |
Ownership Type | Proprietary |
Service Area Zip Codes | 15613, 15729, 15801, 15824, 15825, 15848, 15851, 15857, 16222, 16262, 16301, 16323, 16341, 16342, 16344, 16362, 16374, 16701, 16830, 16881 |
NPI Number | 1417940487 |
Organization Name | INTERIM HEALTHCARE OF WESTERN PENNSYLVANIA INC |
Address | 127 N Brady St, Suite B, Du Bois, PA 15801 |
Phone Number | 814-375-9615 |
News Archive
Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.
A team of researchers led by Patrick E. H. Jackson at the Myles H. Thaler Center for HIV and Human Retrovirus Research, University of Virginia, Charlottesville, Virginia, USA, has published a review on the subject of the HIV-1 Rev Regulatory complex (dubbed the HIV-1 Rev Regulatory Axis) in the journal, Current HIV Research.
The long-term safety of gene transfer to treat neovascular age-related macular degeneration (NVAMD), and the production of two therapeutic proteins encoded by those genes for at least 2.5 years in the eyes of patients with advanced NVAMD are demonstrated in the results of a clinical trial published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Four prominent researchers from UCLA's Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational research awards totaling approximately $13 million from the California Institute for Regenerative Medicine (CIRM) the state stem cell agency. The UCLA researchers received four of the 12 total awards; no other applicant institution received more than one award.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.
› Verified 4 days ago
Quality Rating: | Not Available* |
* The number of patient episodes for this measure is too small to report. |
News Archive
Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.
A team of researchers led by Patrick E. H. Jackson at the Myles H. Thaler Center for HIV and Human Retrovirus Research, University of Virginia, Charlottesville, Virginia, USA, has published a review on the subject of the HIV-1 Rev Regulatory complex (dubbed the HIV-1 Rev Regulatory Axis) in the journal, Current HIV Research.
The long-term safety of gene transfer to treat neovascular age-related macular degeneration (NVAMD), and the production of two therapeutic proteins encoded by those genes for at least 2.5 years in the eyes of patients with advanced NVAMD are demonstrated in the results of a clinical trial published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Four prominent researchers from UCLA's Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational research awards totaling approximately $13 million from the California Institute for Regenerative Medicine (CIRM) the state stem cell agency. The UCLA researchers received four of the 12 total awards; no other applicant institution received more than one award.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.
› Verified 4 days ago
Question Type: | Rating by Patients |
---|---|
Health team gave care in a professional way | Not Available |
Health team communicated well with them | Not Available |
Health team discussed medicines, pain, and home safety | Not Available |
How patients rated overall care from agency | Not Available |
News Archive
Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.
A team of researchers led by Patrick E. H. Jackson at the Myles H. Thaler Center for HIV and Human Retrovirus Research, University of Virginia, Charlottesville, Virginia, USA, has published a review on the subject of the HIV-1 Rev Regulatory complex (dubbed the HIV-1 Rev Regulatory Axis) in the journal, Current HIV Research.
The long-term safety of gene transfer to treat neovascular age-related macular degeneration (NVAMD), and the production of two therapeutic proteins encoded by those genes for at least 2.5 years in the eyes of patients with advanced NVAMD are demonstrated in the results of a clinical trial published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Four prominent researchers from UCLA's Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational research awards totaling approximately $13 million from the California Institute for Regenerative Medicine (CIRM) the state stem cell agency. The UCLA researchers received four of the 12 total awards; no other applicant institution received more than one award.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.
› Verified 4 days ago
The patient survey data of Interim Healthcare Of Western Pa is compared against the national average with the color code indicators: Better than National Average Worse than National AverageExperience Measure | Provider | National Avg. |
---|---|---|
Percent of patients who reported that their home health team gave care in a professional way | 91 | 88 |
Percent of patients who reported that their home health team communicated well with them | 92 | 85 |
Percent of patients who reported that their home health team discussed medicines, pain, and home safety with them | 78 | 83 |
Percent of patients who gave their home health agency a rating of 9 or 10 on a scale from 0 (lowest) to 10 (highest) | 92 | 84 |
Percent of patients who reported YES, they would definitely recommend the home health agency to friends and family | 83 | 78 |
News Archive
Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.
A team of researchers led by Patrick E. H. Jackson at the Myles H. Thaler Center for HIV and Human Retrovirus Research, University of Virginia, Charlottesville, Virginia, USA, has published a review on the subject of the HIV-1 Rev Regulatory complex (dubbed the HIV-1 Rev Regulatory Axis) in the journal, Current HIV Research.
The long-term safety of gene transfer to treat neovascular age-related macular degeneration (NVAMD), and the production of two therapeutic proteins encoded by those genes for at least 2.5 years in the eyes of patients with advanced NVAMD are demonstrated in the results of a clinical trial published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Four prominent researchers from UCLA's Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research have received Early Translational research awards totaling approximately $13 million from the California Institute for Regenerative Medicine (CIRM) the state stem cell agency. The UCLA researchers received four of the 12 total awards; no other applicant institution received more than one award.
Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.
› Verified 4 days ago
Peritech Home Health Associates, Inc. Location: 375 Beaver Drive, Suite 300, Dubois, Pennsylvania 15801 Ratings: NA Phone: (814) 375-1040 | |
Interim Healthcare Of Western Pa Location: 127 North Brady Street Ste B, Dubois, Pennsylvania 15801 Ratings: NA Phone: (814) 375-9615 | |
Aveanna Healthcare Location: 635 South Brady Street, Dubois, Pennsylvania 15801 Ratings: NA Phone: (855) 427-4234 |